CALT - Calliditas Therapeutics AB - ADR
Previous close
40.52
0 0%
Share volume: 4,417
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$40.52
0.00
0.00%
Fundamental analysis
21%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
15%
Performance
5 Days
-0.86%
1 Month
5.30%
3 Months
4.28%
6 Months
83.36%
1 Year
141.25%
2 Year
150.91%
Key data
Stock price
$40.52
DAY RANGE
N/A - N/A
52 WEEK RANGE
$15.25 - $41.90
52 WEEK CHANGE
$1.45
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Renee J. Aguiar-Lucander
Region: US
Website: https://www.calliditas.se/
Employees: 46
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.calliditas.se/
Employees: 46
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Recent news